Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-02-01
2005-02-01
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S212050, C514S214020, C514S214030, C514S286000, C514S288000, C540S468000, C540S472000, C540S477000, C540S544000, C540S556000, C540S576000, C540S596000, C540S604000, C546S063000, C548S421000, C548S424000, C548S425000
Reexamination Certificate
active
06849619
ABSTRACT:
The present invention is directed to certain novel compounds represented by structural Formula (I)or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, R8, R9, X, b, k, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
REFERENCES:
patent: 3299078 (1967-01-01), Pachter
patent: 3914421 (1975-10-01), Rajagopalan
patent: 4013652 (1977-03-01), Rajogopalan
patent: 4088647 (1978-05-01), Glushkov et al.
patent: 4115577 (1978-09-01), Rajogopalan
patent: 4183936 (1980-01-01), Rajogopalan
patent: 4219550 (1980-08-01), Rajogopalan
patent: 4238607 (1980-12-01), Rajogopalan
patent: 4997831 (1991-03-01), Bays et al.
patent: 5100884 (1992-03-01), Hamminga et al.
patent: 5223625 (1993-06-01), Van Wijngaarden et al.
patent: 5328905 (1994-07-01), Hamminga et al.
patent: 6407092 (2002-06-01), Hester et al.
patent: 2011107 (1991-08-01), None
patent: 0725068 (1996-08-01), None
patent: 2213283 (1974-02-01), None
patent: 0064899 (2000-11-01), None
patent: 0077001 (2000-12-01), None
Hoyer, D. et al., “VII International Union of Pharmacology Classification of Receptors . . . ”, Pharmacological Reviews, vol. 46, No. 2, Jun. 1, 1994, pp. 157-203 XP000604197.
Jenck, F. et al., “The Role of 5-HT2C Receptors in Affective Disorders”, Exp. Opin. Ther. Patents, vol. 7, No. 10, 1998, pp. 1587-1599 XP002210253.
Martin, J.R. et al., “5-HT2C Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential”, J. Pharmacol. Exp. Ther., vol. 286, No. 2, Aug. 1996, pp. 913-924 XP00221024.
Cacciola Joseph
Chen Wenting
Fevig John M.
Lee Taekyu
Mitchell Ian S.
Bristol--Myers Squibb Company
Duncan, Jr. Sammy G.
Patel Sudhaker B.
Raymond Richard L.
LandOfFree
Substituted pyridoindoles as serotonin agonists and antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyridoindoles as serotonin agonists and antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyridoindoles as serotonin agonists and antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3474861